

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Roger E. TULLY

Serial Number: to be assigned Group Art Unit: to be assigned

Filed: concurrently herewith Examiner: to be assigned

For: ORAL LIQUID MEDICINE SOLUTION

JC526 U.S. PTO
09/106172
06/26/98

#5

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner of Patents
Washington, D.C. 20231

June 26, 1998

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. These references were cited in a Search Report for the corresponding European application. Copies of the Search Report and cited references are enclosed.


No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

Express Mail No.
EL042439835US

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,


Mary E. Gormley
Attorney for Applicants
Registration No. 34,409

Attorney Docket No. O/97293 US

Akzo Nobel Patent Department
1300 Piccard Drive
Suite 206
Rockville, Maryland 20850
Tel: (301) 948-7400
Fax: (301) 948-9751

MEG/ms

68tully.ids

Express Mail No.
EL042439835US